title: Basophils and plasmacytoid dendritic cells are potential sources for error in flow cytometric monitoring of patients receiving anti-CD22 therapies. AKA not all anti-CD22 antibodies are created equal.
authors.affiliation: Penn State Milton S. Hershey Medical Center, Pathology and Laboratory Medicine, USA. maconlaws@zoho.com
authors.forename: Malcolm
authors.initials: M
authors.lastname: Acon-Laws
authors.forename: Michael G
authors.initials: MG
authors.lastname: Bayerl
authors.forename: Christopher
authors.initials: C
authors.lastname: Ehman
authors.forename: Jozef
authors.initials: J
authors.lastname: Malysz
authors.forename: Cinda
authors.initials: C
authors.lastname: Boyer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology* / Q000494:pharmacology; D001491:Basophils / Q000166:cytology / Q000276:immunology*; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D000080045:Inotuzumab Ozogamicin; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D051918:Sialic Acid Binding Ig-like Lectin 2; D000080045:Inotuzumab Ozogamicin